June 2015 Company Announcements Office Australian Securities Exchange Notice under Section 708A(5)(e) Corporations Act In relation to the ordinary share issuances detailed in the Appendix 3Bs released on 4 th , 5 th , 10
Monday, June 15, 2015 BiopharmaWatch Research 1 min read
Key Takeaway: Announcements Office
Australian Securities Exchange
Notice under Section 708A(5)(e) Corporations Act
In relation to the ordinary share issuances detailed in the Appendix 3Bs released on 4th, 5th, 10th and 11th June 2015, Prima BioMed Ltd ( the Company ) gives notice under
sec
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+76%
120-day peak, hindsight
Typical move
5.4%
average across 13 past catalysts
Lead asset
eftilagimod alfa
Phase 3 · Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
Full Press Release Details
Announcements Office
Australian Securities Exchange
Notice under Section 708A(5)(e) Corporations Act
In relation to the ordinary share issuances detailed in the Appendix 3Bs released on 4th, 5th, 10th and 11th June 2015, Prima BioMed Ltd ( the Company ) gives notice under
section 708A(5)(e) of the Corporations Act 2001 (Cth) (the Corporations Act ) that: